Converge Bio raised $25 million in Series A funding to accelerate AI-driven drug discovery.
- Amount
- $25M
- Stage
- Series A
- Announced
- 13 January 2026
- Lead
- Bessemer Venture Partners
- Other investors
- TLV Partners, Vintage Investment Partners, Saras Capital
- Use of funds
- Expanding platform capabilities, scaling the team, and deepening pharma and biotech partnerships.
- Total raised
- $30M to date
- Checked
- Amount and date matched across 2 press sources